Structural modification of indomethacin toward selective inhibition of COX-2 with a significant increase in van der Waals contributions.
(E)-trimethyl (3,3,3-trifluoroprop-1-enyl)silane
3,3,3-Trifluoroprop-1-enyl group
COX-2 selective inhibition
Indomethacin
van der Waals contribution
Journal
Bioorganic & medicinal chemistry
ISSN: 1464-3391
Titre abrégé: Bioorg Med Chem
Pays: England
ID NLM: 9413298
Informations de publication
Date de publication:
01 05 2019
01 05 2019
Historique:
received:
18
01
2019
revised:
08
03
2019
accepted:
09
03
2019
pubmed:
23
3
2019
medline:
23
2
2020
entrez:
23
3
2019
Statut:
ppublish
Résumé
We have synthesized a fluorinated analogue of indomethacin bearing a 3,3,3-trifluoroprop-1-enyl group at its 2-position and evaluated its inhibitory activity towards the COX-1 and COX-2 enzymes in vitro. The results revealed that this fluorinated analogue exhibited much greater inhibitory activity and selectivity towards COX-2 than indomethacin. The increased affinity between the fluorinated analogue and COX-2 was attributed to a significant increase in van der Waals contacts (i.e. van der Waals contributions in ΔG were -13.80 kcal/mol for COX-1 and -18.46 kcal/mol for COX-2), explaining an effect of the fluorine substituent in enzyme selectivity. This newly synthesized fluorinated analogue therefore represents a potent and selective COX-2 inhibitor.
Identifiants
pubmed: 30898436
pii: S0968-0896(19)30095-1
doi: 10.1016/j.bmc.2019.03.021
pii:
doi:
Substances chimiques
Cyclooxygenase 2 Inhibitors
0
Cyclooxygenase 1
EC 1.14.99.1
Cyclooxygenase 2
EC 1.14.99.1
Indomethacin
XXE1CET956
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1789-1794Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.